- 2025
-
Press releases - 07.05.2025
A new class of molecules against cancer cells refractory to standard treatments
A new class of molecules capable of killing the cancer cells that are refractory to standard treatments and responsible for recurrence has just been developed by scientists at Institut Curie, the CNRS, and Inserm.
-
Press releases - 30.04.2025
Hyperglycémie : vers une meilleure compréhension de son impact délétère sur la peau
Tackling HIV continues to be a major public health challenge, mainly because the persistence of viral reservoirs means that people living with HIV need to take lifelong antiretroviral treatment. But some individuals, known as “post-treatment controllers,” are able to maintain an undetectable viral load even after stopping treatment. Scientists from the Institut Pasteur, Inserm and the Paris Public Hospital Network (AP-HP) identified specific immunogenetic characteristics in a group of these individuals.
-
Press releases - 29.04.2025
HIV: genetic characteristics associated with sustained HIV remission after stopping treatment
Tackling HIV continues to be a major public health challenge, mainly because the persistence of viral reservoirs means that people living with HIV need to take lifelong antiretroviral treatment. But some individuals, known as “post-treatment controllers,” are able to maintain an undetectable viral load even after stopping treatment. In a study funded by ANRS Emerging Infectious Diseases (ANRS MIE), scientists from the Institut Pasteur, Inserm and the Paris Public Hospital Network (AP-HP) identified specific immunogenetic characteristics in a group of these individuals.
-
Press releases - 08.04.2025
Certain food additive mixtures may be associated with an increased risk of type 2 diabetes
Food additive mixtures are an everyday feature of our diets, especially through ultra-processed foods. In a new study, researchers from Inserm, INRAE, Sorbonne Paris Nord University, Paris Cité University and Cnam, as part of the Nutritional Epidemiology Research Team (CRESS-EREN), examined the possible links between exposure to mixtures of commonly consumed food additives and the onset of type 2 diabetes. They analysed the health data of over 100 000 adults participating in the French NutriNet-Santé cohort.
-
Press releases - 30.03.2025
Artificial intelligence in the prevention of sudden death
Many cases of sudden cardiac death could be avoided thanks to artificial intelligence. As part of a new study to be published in European Heart Journal, a network of artificial neurons imitating the human brain was developed by researchers from Inserm, Paris Cité University and the Paris public hospitals group (AP-HP), in collaboration with their colleagues in the USA.
-
Press releases - 26.02.2025
Macrophages: The immune system foodies
Macrophages, key cells of the immune system, play a central role in cleaning the body by ingesting and destroying pathogens (bacteria, viruses, etc.) and damaged cells. Scientists from Inserm, CNRS and the University of Bordeaux, in collaboration with international teams, reveal that this well-known role is accompanied by another surprising ability: in order to support their activity and metabolism, macrophages are capable of sourcing nutrients directly via the breakdown of the ingested bacteria.
-
Press releases - 20.02.2025
Cognitive biases in healthcare: How generative AI could help improve treatment
Human cognitive biases can particularly affect decision-making when speed is of the essence, such as when lives are at stake in a medical emergency. A research team from Inserm and the University of Bordeaux has tested an advanced method of generative artificial intelligence (AI) , trained with data from patient records corresponding to 480 000 entries to the Bordeaux University Hospital Emergency Department.
-
Press releases - 04.02.2025
Lou Gehrig’s disease or Amyotrophic Lateral Sclerosis: sleep alterations occurs prior to motor symptoms
Amyotrophic Lateral Sclerosis (ALS), Charcot’s disease, or Lou Gehrig’s disease is a severe neurodegenerative disease that leads to progressive paralysis of muscles involved in voluntary movement. To date, no curative treatment exists. The disease is typically fatal within three to five years of onset. Researchers from Inserm and University of Strasbourg, at the Center for Biomedical Research, have made progress in understanding the mechanisms underlying ALS. In a new study, they reveal that characteristic symptoms of the disease are preceded by sleep disturbances. Their findings suggest that sleep disorders appear before the onset of motor impairment and respiratory issues. This study highlights a previously unknown role of certain hypothalamic neurons in the emergence of these ALS-related sleep disturbances. Published in Science Translational Medicine, this research identifies new potential therapeutic targets in the brain and explores a novel class of molecules to counteract the effects of sleep deprivation.
-
Press releases - 27.01.2025
The microbiota, an ally for predicting individual sensitivity to food additives
Widely used by the food industry, emulsifiers – a type of food additive – are found in many everyday foods. Given their omnipresence in our diet, the health effects of their consumption have become a real public health issue. Benoit Chassaing, Inserm Research Director and leader of the Microbiome-Host Interactions team at Institut Pasteur (Inserm/Université Paris Cité/CNRS), has previously shown that by acting directly on our gut microbiota, these additives could promote the development of chronic inflammatory diseases and metabolic deregulations. In a new study published in Gut, he and his team developed a human microbiota model capable of predicting each person’s sensitivity to an emulsifier, using a simple stool sample.
- 2024
-
Press releases - 09.12.2024
MASH Discovery Redefines Subtypes with Distinct Risks : Shaping the Future of Fatty Liver Disease Treatment
MASH, formerly known as NASH, is a serious chronic liver disease that affects around 4-6% of the world’s adult population. A new study reveals that, contrary to what was previously thought, there is not just one form of MASH, but two. They differ both in terms of biological characteristics and progression. One is of genetic origin, while the other is the consequence of metabolic disorders. This discovery, made at Lille University Hospital as part of the RHU PreciNASH, a vast hospital-university research project coordinated by Inserm, required the collaboration of several scientific teams from Inria, CNRS, the university, the university hospital and the Pasteur Institute of Lille.